Skip to content
Triangle logo TriangleGet started
← Study library

NCT00676806 · REGISTRY CONDITION SEARCH

A Phase II Study of Umbilical Cord Blood Transplantation

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase
PHASE2
Status at capture
TERMINATED
Registry last update
2017-06-01

This study is designed to determine whether Umbilical Cord Transplantation (UCB) can be substituted for adult bone marrow cells in the standard stem cell transplant regimens used at this hospital for subjects who do not have stem cell donors.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Number of Participants With Neutrophil Engraftment

→

outcome · POSTED

Proportion of Subjects With Platelet Engraftment

→

outcome · POSTED

Incidence of Acute GVHD

→

outcome · POSTED

Infectious Complications in UCB Recipients.

→

outcome · POSTED

Incidence of Chronic GVHD

→

outcome · POSTED

Compare Rates of Complications Between Patients Receiving Ablative vs. Non-myeloablative Conditioning Prior to UCB Transplantation

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→
Who could take part
eligibility Criteria
Inclusion Criteria: Patients meeting eligibility criteria for unrelated allogeneic stem cell transplantation may be considered for participation on this clinical trial if and only if they meet each of the following criteria: * Patients must have one of the following diagnoses * Relapsed or refractory hematologic malignancy, or * High risk hematologic malignancy in first remission, or * Refractory acquired marrow failure state, or * Inherited disorder of metabolism or marrow failure state without alternative curative therapy. * Patients must not have a 6/6 or 5/6 HLA-matched related donor. * Patients must not have a HLA-A, -B and -DRB1 high resolution matched unrelated donor following registry search, or cannot (in the opinion of the treating physician) wait the median 3 months to receive a MUD unit. * Patients must demonstrate an ability to understand and willingness to sign the informed consent document Patients considered for myeloablative conditioning must satisfy the following additional criteria: * Patients must be up to age 55 (inclusive) * Patients must have serum direct bilirubin ≤ 2.0 mg/dl and transaminases ≤ 2x institution upper limit of normal * Patients must have serum creatinine ≤ 2 mg/dl with creatinine clearance ≥ 60 ml/min (either calculated or measured). * Patients must have MUGA scan or echocardiogram normal for the institution, but not less than 45% left ventricular ejection fraction and no clinical evidence of cardiac dysfunction. * Patients must have an ECOG performance status of 0 or 1 (see Appendix C). * Patients must have adequate pulmonary function when corrected for hemoglobin and alveolar volume as evidenced by a diffusion capacity and FEV1 \> 50% of predicted. Patients considered for reduced-intensity conditioning must satisfy the following additional criteria: * Patients must not be candidates for myeloablative conditioning due to any one of the following: Prior myeloablative stem cell transplantation, Age \> 50, Co morbid illness * In opinion of treating physician, unable to comply with or withstand rigors of myeloablative conditioning * Patients with leukemia must have circulating and bone marrow blast counts \< 5%, all other patients must have chemotherapy responsive disease * Patients must be between the ages of 18 and 70 (inclusive) * Patients must have serum direct bilirubin ≤ 2.0 mg/dL and transaminases ≤ 3x institution upper limit of normal * Patients must have creatinine clearance ≥ 30 ml/min (either calculated or measured). * Patients must have MUGA scan or echocardiogram documenting left ventricular ejection fraction of no less than 35% and no clinical evidence of cardiac dysfunction. Patients must have an ECOG performance status of 0 or 1 (see Appendix C). Patients must have adequate pulmonary function when corrected for hemoglobin and alveolar volume as evidenced by a diffusion capacity and FEV1 ≥ 40% of predicted. Exclusion Criteria: Patients are ineligible for participation on this trial if they meet any of the following criteria: * Patients with a history of myocardial infarction within the preceding 6 months, significant arrhythmia within the preceding 3 months, uncontrolled hypertension or congestive heart failure are ineligible. * Patients with unstable angina are not eligible. * Pregnant or lactating women are ineligible. * Male and female patients who do not agree to practice approved methods of birth control for the duration of the study are ineligible. * Patients with uncontrolled infection are ineligible. * Patients who are HIV positive or have evidence of chronic viral hepatitis are ineligible. * Patients unable to comply with requirements for compliance with therapeutic plan and/or scheduled evaluations
healthy Volunteers
false
maximum Age
70 Years
sex
ALL
std Ages
  1. CHILD
  2. ADULT
  3. OLDER_ADULT
Treatment arms and interventions
arm Groups
  1. description
    Umbilical cord blood for hematopoietic rescue following myeloablative conditioning
    intervention Names
    1. Biological: Umbilical Cord Blood After Myeloablative Conditioning
    label
    Myeloablative conditioning
    type
    EXPERIMENTAL
  2. description
    Umbilical cord blood for hematopoietic rescue following non-myeloablative conditioning
    intervention Names
    1. Biological: Umbilical Cord Blood After Reduced-Intensity Conditioning
    label
    Reduced intensity conditioning
    type
    EXPERIMENTAL
interventions
  1. arm Group Labels
    1. Myeloablative conditioning
    description
    cyclophosphamide (60mg/m2 days -6 \& -5), fludarabine (25 mg/m2 days -7, -6, \& -5) and total body irradiation (days -3, -2, \& -1, total 1200 cGy) followed by cord blood infusion on day 0.
    name
    Umbilical Cord Blood After Myeloablative Conditioning
    other Names
    1. Cytoxan
    2. TBI
    3. Fludara
    4. Busulfex
    5. UCBT
    type
    BIOLOGICAL
  2. arm Group Labels
    1. Reduced intensity conditioning
    description
    Extracorporeal Photopheresis (days -8 \& -7), cyclophosphamide 50 mg/kg (day -6) pentostatin 4 mg/kg/d (continuous infusion days -5 \& -4), total body irradiation (days -3 \& -2, total 600cGy) followed by Umbilical Cord Blood Infusion day 0.
    name
    Umbilical Cord Blood After Reduced-Intensity Conditioning
    other Names
    1. Psoralen
    2. Cytoxan
    3. Nypent
    4. TBI
    5. UCBT
    type
    BIOLOGICAL
Study design
allocation
NON_RANDOMIZED
intervention Model
PARALLEL
masking Info
masking
NONE
primary Purpose
TREATMENT
Enrollment
count
7
type
ACTUAL
Registered outcome plans (not posted results)
primary Outcomes
  1. description
    Number of participants with neutrophil engraftment receiving umbilical cord blood for hematopoietic rescue following myeloablative or non-myeloablative conditioning
    measure
    Number of Participants With Neutrophil Engraftment
    time Frame
    +45 and 90 days
secondary Outcomes
  1. description
    Proportion of patients engrafting by days +45, +90, and +180.
    measure
    Proportion of Subjects With Platelet Engraftment
    time Frame
    +45, 90, and 180 days
  2. measure
    Incidence of Acute GVHD
    time Frame
    Day +100
  3. measure
    Infectious Complications in UCB Recipients.
    time Frame
    Day +100
  4. measure
    Incidence of Chronic GVHD
    time Frame
    After Day +100
  5. description
    Composite endpoint of GVH or infection. Too few events to compare between arms.
    measure
    Compare Rates of Complications Between Patients Receiving Ablative vs. Non-myeloablative Conditioning Prior to UCB Transplantation
    time Frame
    +180 days
Full study description
brief Summary
This study is designed to determine whether Umbilical Cord Transplantation (UCB) can be substituted for adult bone marrow cells in the standard stem cell transplant regimens used at this hospital for subjects who do not have stem cell donors.
detailed Description
Allogeneic stem cell transplantation (SCT) following myeloablative and non-myeloablative conditioning therapy has proven curative treatment for a number of inherited and acquired hematologic disorders. The success of allogeneic transplantation is largely determined by compatibility between donor and recipient, which predicts the risk of fatal graft-versus-host disease (GVHD). Unfortunately, less than one third of patients needing an allogeneic transplant have an available compatible donor in their family. Registries have been established to match patients with compatible volunteer (unrelated) donors, but many patients, and in particular minority patients, still lack stem cell donors. Umbilical cord blood (UCB) is a rich source of hematopoietic stem cells, which is readily available from the placenta following childbirth. Blood banks have been established in the United States and abroad to collect, process and store UCB for use in allogeneic transplantation. To date, more than 2000 UCB transplants have been performed in adults and children around the world. Rationale for use of Umbilical Cord Blood in Transplantation UCB has a number of proven and theoretical advantages as an alternative source of hematopoietic stem cells for transplantation: 1. Placental or umbilical cord blood is an abundantly available source of stem cells, which is currently discarded and can be harvested at no risk to the mother or infant. 2. Important infectious agents, particularly CMV, are much less common in the newborn than adults, and are less likely to contaminate UCB collections. 3. UCB collections, typed, cryopreserved and banked, are available on demand, eliminating delays and uncertainties that now complicate marrow collection from unrelated donors. At present, UCB can be delivered for infusion within days of the initiation of a search. This compares with a median of 3 months from search to delivery of stem cells through the registries of volunteer adult donors. 4. The intensity of graft-versus-host reactivity of fetal lymphocytes appears to be less than that of adult cells and consequently fetal lymphocytes are more tolerant of HLA incompatibility. Published studies have shown that transplantation of UCB matched at 4-5/6 antigens results in a comparable incidence of GVHD to transplantation of unrelated stem cells fully matched at 6/6 antigens. 5. Frozen UCB can be easily shipped, stored at the treating institution, and thawed for use when needed, compared to freshly donated stem cells which have a limited shelf-life of one day or less, necessitating coordination between harvesting surgeons, transportation, and transplantation teams. This research study has been designed for people who have been diagnosed with a blood tumor, which has not responded to treatment or has recurred, a bone marrow failure state such as aplastic anemia, or one of certain inherited metabolic disorders; and whose doctor feels the best treatment is an allogeneic stem cell transplant (alloSCT) but a related or unrelated adult donor is not available. Instead, a single unit of umbilical cord blood (UCB) will be used as the source of the subject's immune system. This study is designed to determine whether a single unit of UCB can be substituted for adult bone marrow cells in the standard stem cell transplant regimens used at this hospital for subjects who do not have stem cell donors.
Source references
Source notices and limitations
    Discovery and provenance
    1. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-fa914c0718874a0d3c17
      requested nct id
      NCT00676806
      primary nct id
      NCT00676806
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
      payload sha256
      0d155ba9c974a3f8d3934c645e139ddc492295c8f8a4e5f194158cc01d649d94
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-fa914c0718874a0d3c17
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT00676806
      occurrences
      1. context exact
        NCT00676806
        end
        11
        exact text
        NCT00676806
        start
        0
      offset unit
      unicode_code_points
      query cond
      Plasma Cell Neoplasms
      query disease state id
      ds-plasma-cell-neoplasms
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-plasma-cell-neoplasms-000.json
      source file sha256
      2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
      source json pointer
      /studies/51/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      627974a6a385179c0faf244c0853516dbbd3dd081f082ff95cc75ad7055241f1

    Preserved source evidence · Not medical advice